Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 09 Aug 2017 Planned End Date changed from 1 Apr 2023 to 1 Jul 2018.
- 09 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.